Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;33(4):461-470.
doi: 10.1007/s10557-019-06876-y.

Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial

Gavin A Lewis  1   2 , Erik B Schelbert  3   4   5 , Josephine H Naish  1 , Emma Bedson  6 , Susanna Dodd  7 , Helen Eccleson  6 , Dannii Clayton  6 , Beatriz Duran Jimenez  2 , Theresa McDonagh  8 , Simon G Williams  2 , Anne Cooper  9 , Colin Cunnington  1   2 , Fozia Zahir Ahmed  1   2 , Rajavarma Viswesvaraiah  10 , Stuart Russell  11 , Stefan Neubauer  12 , Paula R Williamson  7 , Christopher A Miller  13   14   15
Affiliations

Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial

Gavin A Lewis et al. Cardiovasc Drugs Ther. 2019 Aug.

Abstract

Background: The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy and safety of the anti-fibrotic pirfenidone in patients with chronic heart failure and preserved ejection fraction (HFpEF) and myocardial fibrosis. HFpEF is a diverse syndrome associated with substantial morbidity and mortality. Myocardial fibrosis is a key pathophysiological mechanism of HFpEF and myocardial fibrotic burden is strongly and independently associated with adverse outcome. Pirfenidone is an oral anti-fibrotic agent, without haemodynamic effect, that leads to regression of myocardial fibrosis in preclinical models. It has proven clinical effectiveness in pulmonary fibrosis.

Methods: The PIROUETTE trial is a randomised, double-blind, placebo-controlled phase II trial evaluating the efficacy and safety of 52 weeks of treatment with pirfenidone in patients with chronic HFpEF (symptoms and signs of heart failure, left ventricular ejection fraction ≥ 45%, elevated natriuretic peptides [BNP ≥ 100 pg/ml or NT-proBNP ≥ 300 pg/ml; or BNP ≥ 300 pg/ml or NT-proBNP ≥ 900 pg/ml if in atrial fibrillation]) and myocardial fibrosis (extracellular matrix (ECM) volume ≥ 27% measured using cardiovascular magnetic resonance). The primary outcome measure is change in myocardial ECM volume. A sub-study will investigate the relationship between myocardial fibrosis and myocardial energetics, and the impact of pirfenidone, using 31phosphorus magnetic resonance spectroscopy.

Discussion: PIROUETTE will determine whether pirfenidone is superior to placebo in relation to regression of myocardial fibrosis and improvement in myocardial energetics in patients with HFpEF and myocardial fibrosis (NCT02932566).

Clinical trial registration: clinicaltrials.gov (NCT02932566) https://clinicaltrials.gov/ct2/show/NCT02932566.

Keywords: Fibrosis; Heart failure; Magnetic resonance imaging (MRI).

PubMed Disclaimer

Conflict of interest statement

This study was supported with provision of pirfenidone by Roche Products Limited. Roche Products Ltd. was not involved in the preparation, drafting, or editing of this manuscript. Roche Products Ltd. has conducted a factual accuracy check on the final article, but any decisions to incorporate comments were made solely at the discretion of the authors.

Figures

Fig. 1
Fig. 1
HFpEF pathophysiological mechanism being targets, mechanism of action of pirfenidone and study schematic. Asterisk indicates MMPs, TIMPs, interleukins, renin-angiotensin-aldosterone system
See this image and copyright information in PMC

References

    1. Butler J, Hamo CE, Udelson JE, O’Connor C, Sabbah HN, Metra M, et al. Reassessing phase II heart failure clinical trials: consensus recommendations. Circ Heart fail. 2017;10(4):e003800. - PMC - PubMed
    1. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013;10(2):85–97. - PubMed
    1. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA. 2013;309(15):1593–1594. - PubMed
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members. Document Reviewers 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary. J Am Coll Cardiol. 2013;62(16):1495–1539. - PubMed

Associated data